| A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy RD Leone, YC Lo, JD Powell Computational and structural biotechnology journal 13, 265-272, 2015 | 267 | 2015 |
| Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation KN Pollizzi, IH Sun, CH Patel, YC Lo, MH Oh, AT Waickman, AJ Tam, ... Nature immunology 17 (6), 704-711, 2016 | 246 | 2016 |
| Preventing allograft rejection by targeting immune metabolism CF Lee, YC Lo, CH Cheng, GJ Furtmüller, B Oh, V Andrade-Oliveira, ... Cell reports 13 (4), 760-770, 2015 | 197 | 2015 |
| Distinct signaling mechanisms regulate migration in unconfined versus confined spaces WC Hung, SH Chen, CD Paul, KM Stroka, YC Lo, JT Yang, ... Journal of cell biology 202 (5), 807-824, 2013 | 170 | 2013 |
| Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC G Recondo, M Bahcall, LF Spurr, J Che, B Ricciuti, GC Leonardi, YC Lo, ... Clinical Cancer Research 26 (11), 2615-2625, 2020 | 151 | 2020 |
| Tumor-infiltrating lymphocytes and PD-L1 expression in pre-and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial V Pelekanou, WE Barlow, ZA Nahleh, B Wasserman, YC Lo, ... Molecular cancer therapeutics 17 (6), 1324-1331, 2018 | 93 | 2018 |
| Targeting glutamine metabolism rescues mice from late-stage cerebral malaria EB Gordon, GT Hart, TM Tran, M Waisberg, M Akkaya, AS Kim, ... Proceedings of the National Academy of Sciences 112 (42), 13075-13080, 2015 | 84 | 2015 |
| Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation R Ng, H Manring, N Papoutsidakis, T Albertelli, N Tsai, CJ See, X Li, ... JCI insight 4 (14), 2019 | 40 | 2019 |
| Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection YC Lo, CF Lee, JD Powell Current opinion in organ transplantation 19 (4), 363-371, 2014 | 39 | 2014 |
| Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images CS Velmahos, M Badgeley, YC Lo Cancer Medicine 10 (14), 4805-4813, 2021 | 35 | 2021 |
| Acute alachlor and butachlor herbicide poisoning YC Lo, CC Yang, JF Deng Clinical toxicology 46 (8), 716-721, 2008 | 34 | 2008 |
| Selective activation of antigen-experienced T cells by anti-CD3 constrained on nanoparticles YC Lo, MA Edidin, JD Powell The Journal of Immunology 191 (10), 5107-5114, 2013 | 32 | 2013 |
| Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer ZP Lin, YL Zhu, YC Lo, J Moscarelli, A Xiong, Y Korayem, PH Huang, ... PLoS One 13 (11), e0207399, 2018 | 29 | 2018 |
| Biomarker driven treatment of head and neck squamous cell cancer N Eze, YC Lo, B Burtness Cancers of the head & neck 2, 1-12, 2017 | 29 | 2017 |
| Tepotinib Efficacy in a Patient with Non‐Small Cell Lung Cancer with Brain Metastasis Harboring an HLA‐DRB1‐MET Gene Fusion F Blanc‐Durand, R Alameddine, AJ Iafrate, D Tran‐Thanh, YC Lo, N Blais, ... The Oncologist 25 (11), 916-920, 2020 | 26 | 2020 |
| Late complications of COVID-19: a morphologic, imaging, and droplet digital polymerase chain reaction study of lung tissue AC Roden, JM Boland, TF Johnson, MC Aubry, YC Lo, YM Butt, ... Archives of pathology & laboratory medicine 146 (7), 791-804, 2022 | 20 | 2022 |
| Checkpoint inhibitor colitis shows drug-specific differences in immune cell reaction that overlap with inflammatory bowel disease and predict response to colitis therapy YC Lo, C Price, K Blenman, P Patil, X Zhang, ME Robert American Journal of Clinical Pathology 156 (2), 214-228, 2021 | 15 | 2021 |
| Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient A Anderson, D McManus, S Perreault, YC Lo, S Seropian, JE Topal Medical mycology case reports 17, 11-13, 2017 | 13 | 2017 |
| Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. V Pelekanou, WE Barlow, MK von Wahlde, B Wasserman, YC Lo, ... Journal of Clinical Oncology 35 (15_suppl), 519-519, 2017 | 8 | 2017 |
| A 49-year-old man with subacute respiratory failure and interstitial lung opacities AA Rudkovskaia, YC Lo, V Brady, J Costa, WH Fares The American Journal of Case Reports 18, 941, 2017 | 8 | 2017 |
